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The prevalence of atrial ﬁbrillation (AF) is increasing in parallel with an ageing population leading to increased morbidity and
mortality. The most feared complication of AF is stroke, with the arrhythmia being responsible for up to 20% of all ischemic
strokes. An important contributor to this increased risk of stroke is the left atrial appendage (LAA). A combination of the LAA’s
unique geometry and atrial ﬁbrillation leads to low blood ﬂow velocity and stasis, which are precursors to thrombus formation. It
has been hypothesized for over half a century that excision of the LAA would lead to a reduction in the incidence of stroke. It has
only been in the last 20–25 years that the knowledge and technology has been available to safely carry out such a procedure. We
now have a number of viable techniques, both surgical and percutaneous, which will be covered in this paper.
1.Introduction
Atrial ﬁbrillation (AF) is the most prevalent arrhythmia
seen in clinical practice with over 2.2 million people in the
United States being aﬀected [1]. Given the association of
AF with advancing age, this ﬁgure is predicted to increase
signiﬁcantly over the years to come, in line with an aging
population. By 40 years of age, the lifetime risk of a man
developing AF is 26% and a woman 23% [2]. Although most
patients with AF tolerate it well, in a signiﬁcant proportion
of patients the arrhythmia can lead to a substantial reduction
in quality of life. The most signiﬁcant complication, feared
by both patient and medical staﬀ, is that of stroke. A stroke
in a patient with AF has a poorer prognosis than in a
patient without AF [3]. The rhythm had been shown to
increase a patient’s risk of an ischemic stroke by 4-5 fold [4].
Additionally, AF has been shown to be accountable for up to
20% of all ischemic strokes [5].
Oral anticoagulant therapy, most commonly with war-
farin, has been used to reduce the risk of stroke in patients
with nonvalvular AF who are at high risk of thromboem-
bolism [6]. Overall, warfarin is underused in these patients
mainly duetopatient andhealthpractitioner concernsabout
the increased risk of signiﬁcant bleeding with aggressive
anticoagulation. Clinical data has suggested that only 50–
60% of patients who clinically should be prescribed warfarin
are actually taking it [7]. Furthermore, clinical trials have
demonstrated that a signiﬁcant proportion of patients who
are taking warfarin, are not adequately anticoagulated plac-
ing them at an increased risk of stroke. There are now alter-
native medications to warfarin, which are available. Apixa-
ban is an oral factor Xa inhibitor, which has been shown
to be superior to warfarin in preventing stroke or systemic
embolism in patients with nonvalvular AF (1.27% per year
versus 1.60%; P = 0.01 for superiority) [8]. Dabigatran is
a direct thrombin inhibitor and is available in two diﬀerent
doses. The Re-ly trial included 18,113 patients with AF and
a risk of stroke. Patients were randomized to receive either
warfarin, dabigatran 110mg twice daily or 150mg twice
daily. It showed that the lower 110mg dose had similar rates
of stroke and systemic embolism to warfarin (1.52% per year
versus 1.69%; P<0.001 for noninferiority). Furthermore,
the higher 150mg dose was shown to be superior to warfarin
(1.11% per year versus 1.69%; P<0.001 for superiority) [9].2 Cardiology Research and Practice
These agents tend to have a lower incidence of bleeding
with more convenient dosing regimens without the need for
intensive monitoring. However, these agents would not ben-
eﬁt those patients who have a contraindication to anticoagu-
lation, which incorporates between 14–44% of patients with
AF who are at risk of stroke [10]. Even with adequate anti-
coagulation, the risk of stroke is not abolished. The annual
incidence of stroke in patients therapeutically warfarinised
is 2–5% [11]. These issues have led to an increased interest
in alternative treatment strategies to help reduce the risk of
stroke in these patients. The main focus of this interest is on
the left atrial appendage (LAA). It has been shown that more
than 90% of thrombi in patients with nonrheumatic, nonva-
lvular AF are located within this cavity [12]. The LAA forms
during the 3rd week of gestation and temporarily acts as the
leftatrium.Anoutpouchingofthepulmonaryveinsdevelops
into the true left atrium [13] .T h es i z ea n dm o r p h o l o g yo f
theLAAvariesfrompersontopersonandhasbeenmeasured
anywherefrom0.77to19.27cm3.TheLAAisoftendescribed
as being redundant. A number of studies have shown that it
plays an important role in the regulation of the intravascular
volume status as well as hemodynamic conditions. Excision
of the LAA is thought to lead to a reduction in the incidence
of stroke in patients with AF. New techniques have emerged
which have enabled this process to be done percutaneously
without exposing patients to high-risk invasive surgery. Due
to the complexity and variability of the LAA anatomy, multi-
modality imaging techniques play an integral role in the
workup of these patients and directing percutaneous closure.
This is particularly important to ensure correct sizing of a
device and reduce the risk of complications such as device
embolisation or free-wall perforation.
2.SurgicalOptions
Historically, obliteration of the left atrial appendage was ﬁrst
used in conjunction with mitral valvotomy, prior to the
utilization of cardiopulmonary bypass. Madden carried out
the ﬁrst LAA surgical excision in humans in 1949, publishing
2 cases the same year [14]. Initial results were not promising.
The ﬁrst recorded cases had unacceptably high complication
rates, and interest in the procedure waned [15]. Interest in
surgical treatment of AF reignited when James Cox intro-
duced the Cox-Maze procedure at the Barnes-Jewish Hospi-
tal, St. Louis, in 1987. This helps to terminate AF by making
multiple deep incisions in both atria in an attempt to block
the electrical pathways needed to sustain the arrhythmia.
Additionally the Maze procedure usually includes excision or
closure of the LAA. A number of improvements have been
made since, resulting in the Cox-Maze III procedure, which
is still used in clinical practice today [16–19].
The success of the Maze procedure was illustrated in a
retrospective analysis by Cox et al. [20] looking at patients
who underwent the procedure for AF which had been
unsuccessfully treated medically. Three hundred and six
patients were included over an 11-year period, of which 58
hadeitherapreviousstrokeortransientischemicattack.Two
patients were noted to have perioperative strokes (0.7%) and
of the 265 patients who were followed up for up to 11 years,
only 1 patient was recorded as having had a stroke.
An u m b e ro fd i ﬀerent surgical methods have been used
to close the LAA. There are 2 general techniques adopted.
Firstly, excision of the LAA can be performed by either
removing the LAA and oversewing or a stapled excision. Sec-
ondly, exclusion of the LAA can be achieved with sutures or
clips on either the endocardial or epicardial surface, isolating
the LAA from the left atrium. Additionally, small case series
havebeenreportedusingathoracoscopicapproachforexclu-
sion of the leftatrial appendage withoutthe need foranopen
sternotomy. The success of each method has been highly
scrutinized as clinical evidence has questioned their success.
The Left Atrial Appendage Occlusion Study included 77
patients undergoing CABG [21]. They were randomized to
either LAA occlusion or control. The surgical management
of the LAA involved either stapled exclusion or suture
ligation. The surgery was deemed successful in 72% of
the stapled exclusion group compared with 45% in the
suture ligation group. The predominant reason for failure
in the group that underwent suture ligation appeared to
unsatisfactory closure, with persistent Doppler ﬂow within
the appendage seen on echocardiography. Furthermore,
incomplete closure is likely to be more detrimental than not
attempting surgery. A follow-up study looking at patients
who have undergone surgical LAA closure showed that 41%
of patients with an unsuccessful closure had a thrombus
within the LAA on transesophageal echocardiography [22].
The study looked at 137 patients who had either LAA
excision (52 patients = 38%) or exclusion (85 patents =
62%), of which 73 were sutured, and 12 were stapled. There
was a success rate of only 40% (55/137 patients). Surgical
excision was more successful than both suture and staple
exclusion (73% versus 23% versus 0%, resp.).
The poor success of certain LAA exclusion techniques
had previously been suggested by a study looking at a group
of 50 patients who had undergone mitral valve surgery in
addition to ligation of the LAA [23]. A transœsophageal
echocardiogram was performed at a variable time after
procedure, varying from immediately postoperatively to 13
years later. Partial ligation was seen in 36% (18/50 patients)
of patients. Of these, 50% (9/18 patients) demonstrated
spontaneous echo contrast or thrombus within the LAA,
and 22% (4/18 patients) had experienced a thromboembolic
event.
The FDA has approved the use of the AtriClip device
(Articure, West Chester, OH, USA) for closure of the LAA. It
consists of 2 rigid titanium tubes with elastic nitinol springs
covered with a knit-braided sheath. The LAA is inserted
into the device, which then clips at the base, separating the
appendage from the left atrium. The initial trial assessing
the safety and eﬃcacy of the device was carried out in
Europe [24]. It included 34 patients with AF who were
undergoingelectivecardiacsurgeryviaamediansternotomy.
Patients underwent computed tomography studies to assess
the device location as well as looking for evidence of blood
ﬂow within the LAA. Although operative mortality was
8.8%, none of the deaths were attributable to the device.
All patients had successful LAA closure at 3 months. ThereCardiology Research and Practice 3
werenoreportsofstrokeortransientischemicattacksduring
the follow-up period. A further nonrandomized, prospective
multicenter trial was performed in the United States called
the EXCLUDE trial [25]. Again, the study population was
composed of patients who were undergoing primary elective
cardiac operations with a median sternotomy. Additionally
theyhad to have eitherAF or have anincreased risk of stroke,
as measured by the CHADS2 scoring system (CHADS2 >2)
[26]. 71 patients were enrolled across 7 US centers with 1
patient being excluded due to inappropriate LAA anatomy.
LAA exclusion was deemed successful in 67 of the remaining
70 patients (96%). By the 3-month followup, 61 patients
were able to undergo further imaging by either trans-
esophageal echocardiography or computed tomography. At
followup, over 98% of patients had successful exclusion of
the LAA. There were no adverse advents attributable to the
AtriClip procedure.
Newer surgical techniques are still currently under inves-
tigation in an attempt to improve success rates of LAA
closure. One such technique involves invaginating the LAA
into the left atrium prior to applying a purse-string suture
along the base of the LAA [27]. Once this is in place, the LAA
is pulled outwards again and the oriﬁce closed with a second
running suture. This procedure has only been reported on 8
patients, and followup imaging is still pending; however, the
authors remain optimistic about its potential.
Current practice focuses on the excision of the LAA,
given its higher success rates. This usually involves a median
sternotomy and is usually best used in patients who require
an additional cardiac surgery, in light of the associated surgi-
cal risks. As techniques improve and procedures become less
invasive, this may well change. In light of the paucity of long-
term follow-up data following surgical LAA excision and
exclusion: further research is required to deﬁne long-term
outcomes and need for ongoing anticoagulation following
these approaches.
3. PercutaneousManagement
There are a number of devices that are available for closure
of the left atrial appendage (see Table 1). Only the WATCH-
MAN device has been subjected to a randomized controlled
trialagainstawarfarincontrolgroup;withremainingdevices
being assessed by registry data or prospective trials to
assess safety and eﬃcacy. Just three of these devices are
currentlyavailableforclinicaluse.TheseincludetheLARIAT
suture delivery system, the WATCHMAN device, and the
AMPLATZER Cardiac Plug. The LARIAT suture delivery
system is the only device that has, at this time, received both
United States Food and Drug Administration (FDA) and
European Conformit´ eE u r o p ´ eenne (CE) mark regulatory
approval. The other two devices carry European CE mark
approval for their use. The AMPLATZER Cardiac Plug
approval was based on the available registry data. In Aus-
tralia, the Therapeutic Goods Administration has approved
the use of these two devices.
The antiplatelet and anticoagulant regimens used in the
clinical trials varied depending on the device (see Table 2).
Figure1:AMPLATZERseptaloccluder.(AMPLATZERandSt.Jude
Medical, Inc. Reprinted with permission of St. Jude Medical, ©
2011. All rights reserved).
3.1. AMPLATZER Septal Occluder. The AMPLATZER Septal
Occluder (St. Jude Medical, Plymouth, MN, USA) was
initially designed for patent foramen ovale and atrial septal
defect closure. A small trial of 16 patients across 4 centres
assessed its use in left atrial appendage occlusion [28]. A
standard AMPLATZER atrial septal defect occluder with
a neck a few millimetres smaller than the neck of the left
atrial appendage was selected. The left disk of the occluder
was released within the left atrial appendage and right
disk released at the left atrial appendage entrance. A single
technical failure occurred due to inappropriate device sizing
resulting in device embolization and requiring cardiac
surgery for device retrieval. Over a short device follow-up
period of just 4 months, there were no adverse events
attributable to the device implantation or thromboembolic
events noted (Figure 1).
No further clinical trials have been conducted using this
system for left atrial appendage occlusion. A new device, the
AMPLATZER Cardiac Plug, has been designed by the same
manufacturer and is currently undergoing clinical trial (see
below).
3.2. PLAATO. The PLAATO system (eV3, Plymouth, MN,
USA) consists of a percutaneously delivered self-expanding
nitinol cage covered with an expanded polytetraﬂuoroethy-
lene and 3 rows of anchors, delivered via a transseptal ap-
proach.
Initial assessment in a canine model demonstrated
proof of concept with left atrial appendage occlusion being
achieved in all cases. Complete healing over the device’s
membrane surface was demonstrated on both gross and
histological examination in 90% by 1 month and in all cases
by 3-month follow-up [29].
Subsequent human trials demonstrated a high procedu-
ral success rate with successful implantation in 108 of the
111 patients enrolled (97.3%, 95% conﬁdence interval (CI)
92.3% to 99.4%) [30]. Patients were treated with aspirin
(300 to 325mg) indeﬁnitely. North American patients also4 Cardiology Research and Practice
Table 1: Summary of percutaneous devices.
Device Study Design Number of
patients Inclusion criteria Mean F/U Results Comments
LARIAT Lee et al.
[39] Prospective 82
AF; C/I to warfarin
or intolerance to
warfarin or pts
who have had an
embolic event on
whilst on warfarin
3m o n t h s
96% of patients
with successful
closure
continued to
have complete
closure at 1
month
(i) Requires both endocardial and
epicardial access
(ii) Unsuitable in patients with
possible pericardial adhesions
(e.g., prior history of coronary
artery bypass surgery, valvular
surgery, pericarditis, and chest
radiotherapy)
(iii) Clinical trial data pending
(iv) FDA and CE mark
APPROVED for commercial use
WATCHMAN
Reddy et al.
(PROTECT
AF) [33]
RCT 707
Permanent or
paroxysmal AF;
CHADS2 ≥ 1;
suitable for
warfarin
18 months
Probability of
noninferiority
of the
intervention
was more than
99.9%
(i) Eﬃcacy demonstrated in
clinical trial
(ii) CE mark APPROVED for
commercial use
AMPLATZER
cardiac plug
Park et al.
[35] Registry 141 Permanent or
paroxysmal AF
24 hours
after-
implantation
Stroke 2.1%
Device
embolisation
1.4%
Pericardial
tamponade
3.5%
(i) Clinical trial data pending
(ii) CE mark APPROVED for
commercial use
AMPLATZER
septal occluder
Meier et al.
[28] Prospective 16
Permanent or
paroxysmal AF;
C/I to warfarin
4m o n t h s
TIA/stroke 0%
Device
embolisation
6.3%
( i )N o tad e d i c a t e dL A Ao c c l u d e r
(ii) Has been superseded by the
AMPLATZER Cardiac Plug for
LAA occlusion
(iii) Not in Commercial use
PLAATO
Ostermayer
et al. [30] Prospective 111
Permanent
nonrheumatic AF;
patients at risk for
stroke; C/I to
warfarin
10 months TIA/stroke
2.2% (i) No longer available for clinical
use
Block et al.
[31] Prospective 64
Permanent or
paroxysmal AF;
CHADS2 ≥ 2;
C/I to warfarin
5 years Stroke: 3.8%
Coherex Wave
Crest
Muller
(currently
recruiting)
[36]
Prospective
52-
actively
recruiting
Permanent or
paroxysmal
nonvalvular AF;
CHADS2 ≥ 1
Data available
on 10 cases
only, 1 embolic
event
(i) Retractable coils and anchors to
enable optimal device positioning
(ii) Clinical trial data pending
(iii) Not in commercial use
C/I: contraindication and AF: atrial ﬁbrillation.
received 4–6 weeks of Clopidogrel 75mg daily and subacute
endocarditis prophylaxis for the initial six months due to a
possible increase in infective endocarditis risk. For European
patients, the choice of Clopidogrel and endocarditis prophy-
laxiswasleftatthediscretionofthetreatingphysician.Unlike
subsequent trials, warfarin was not routinely prescribed as
part of the trial protocol.
During the initial follow-up period of 90.7 documented
implant years covering the initial postimplant period, there
were 7 major adverse events in 5 patients [31]. This includ-
ed 1 episode of cardiac tamponade following transseptal
puncturenecessitatingemergentcardiovascularsurgery.This
patient subsequently developed a lower limb deep venous
thrombosis and died secondary to cerebral haemorrhage
thought secondary to anticoagulation [31, 32]. Three other
patients underwent in-hospital pericardiocentesis due to a
hemopericardium [31]. Other adverse outcomes included 2
strokes occurring at 173 and 215 days postdevice implan-
tation [31]. Their routine 1-and 6-month follow-up trans-
esophageal echocardiograms had demonstrated stable device
position with no thrombogenic layer on the device surface;
colour ﬂow doppler at six months showed “trace leak”
and “absent leak.” Additionally, three TIAs occurred in
two patients [31]. There were six deaths in 111 patients,Cardiology Research and Practice 5
Table 2: Summary of antiplatelet/anticoagulation requirements and endocarditis prophylaxis for each percutaneous device.
Aspirin Clopidogrel Warfarin Endocarditis Prophylaxis
AMPLATZER septal
occluder [28]
Few months
indeﬁnitely
depending on
treating centre
None, few months
depending on treating
centre
None, 6 weeks depending on
treating centre Few months
PLAATO [30] 300–325mg daily
indeﬁnitely
75mg for 6 months at
North American centres
and at operator’s discretion
at European centres
Nil
6 months at North
American centres and at
operator’s discretion at
European centres
WATCHMAN [33] 81–325mg daily
indeﬁnitely 75mg for 6 months
At least 45 days. Discontinued at 45
days if follow up TEE shows <5mm
of peridevice ﬂow
Nil
AMPLATZER cardiac
plug [35] Not speciﬁed Not speciﬁed Not speciﬁed Not speciﬁed
Coherex Wave Crest 75–325mg daily
indeﬁnitely
75mg daily for 90 days if
not on warfarin
If previously on warfarin with a
history of stroke or TIA, continue
warfarin until LAA closure
demonstrated on TEE
Nil
LARIAT Indeﬁnitely Nil
If previous embolic events whilst on
OAC and no contraindication or
intolerance, OAC continued
regardless of procedural success
Nil
TIA: transient ischaemic attack and OAC: oral anticoagulant.
including cardiac or neurological death (n = 4), secondary
complications after gastrointestinal bleeding (n = 1), and an
incarcerated hernia (n = 1): but none were adjudicated as
related to the device or procedure [31].
At 5-year follow-up of the North American cohort of 64
patients, there were 7 (11%) deaths, 5 (8%) major strokes,
3 (5%) minor strokes, 1 (2%) cardiac tamponade requiring
surgery, 1 (2%), death from probable cerebral haemorrhage,
and 1 (2%) myocardial infarction [32]. Only 1 event (car-
diac tamponade) was adjudicated as related to the implant
procedure. The annualized stroke/transient ischemic attack
(TIA) rate was 3.8%: signiﬁcantly less than an anticipated
stroke/TIA rate of 6.6%/year as estimated by a mean
CHADS2 score of 2.6 in the study population [32].
The PLAATO device has been discontinued for commer-
cial reasons.
3.3. WATCHMAN. The WATCHMAN device (Atritech, Ply-
mouth, MN, USA) is a percutaneous left atrial appendage
c l o s u r es y s t e md e l i v e r e dv i aat r a n s s e p t a la p p r o a c h ,a n d
implanted at or immediately distal to the ostium of the left
atrialappendage.Thedeviceconsistsofaself-expandingniti-
nol frame with ﬁxation barbs and a permeable polyester fab-
ric which covers the atrial facing device surface. The WATH-
MAN device is available in 5 sizes ranging from 21mm to
33mm in diameter, to accommodate patient variation in
left atrial appendage anatomy and size: with device sizing
and placement guided by ﬂuoroscopy and transesophageal
echocardiography.
In light of the permeability of the device membrane
to blood, warfarin is prescribed with a target International
N o r m a l i s e dR a t i o( I N R )o f2 . 0t o3 . 0f o rap e r i o do f4 5d a y s
postdevice implantation to allow endothelialisation of the
device. This is discontinued following this period, if repeat
transesophagealechocardiographydemonstrateseithercom-
plete closure of the left atrial appendage or minimal residual
peridevice ﬂow, deﬁned as a jet width of <5mm. Following
cessation of warfarin treatment, dual antiplatelet therapy
with clopidogrel (75mg daily) and aspirin (81–325mg daily)
was prescribed until completion of the 6-month follow-up
visit, with the use of aspirin alone lifelong thereafter [33].
Evaluation of the WATCHMAN device against a conven-
tionally treated warfarin control population was performed
in the PROTECT-AF trial [33], the ﬁrst trial to randomise
device therapy against conventional therapy. The study
randomised 707 patients, aged 18 years or older with non-
valvular atrial ﬁbrillation and a CHADS2 risk score of ≥1,
in a 2:1 intervention to control ratio. An aggregate follow
up of 1065 patient-years with mean follow up of 18 months
per patient was reported. There was a good procedural
success rate, with successful device implantation in 408
(88%)ofthe463randomisedtoleftatrialappendageclosure.
Following conﬁrmation of left atrial appendage closure on
transesophageal echocardiography, warfarin cessation was
possible in 86%. Warfarin cessation between 45 days and
6 months was attributable mainly to a reduction in peri-
device leak. The WATCHMAN device was determined to
be noninferior to conventional warfarin therapy when com-
paring the primary eﬃcacy endpoint of strokes (ischemic
and haemorrhagic), cardiovascular or unexplained death, or
systemic embolism. The primary eﬃcacy event rate was 3.0
per 100 patient-years (95% CrI 1.9–4.5) in the intervention
group compared with 4.9 per 100 patient-years (95% CrI
2.8–7.1) in control patients receiving warfarin (Figure 2).6 Cardiology Research and Practice
Figure 2: WATCHMAN LAA closure device. (Image courtesy of
Atritech, Inc., © 2011).
However, safety concerns do exist with the placement of
the WATCHMAN device:with an excess of adverse outcomes
in the WATCHMAN device group compared to warfarinised
controls. This is illustrated in the PROTECT-AF trail [33],
where the adverse primary safety events occurred at a rate
of 7.4 per 100 patient-years (95% CrI 5.5–9.7) in the
WATCHMAN group compared with 4.4 per 100 patient-
years (95% CrI 2.5–6.7). Most adverse events (55%) were
directly related to the procedure occurring on the same day
as device implantation. The most frequent adverse outcome
was that of a signiﬁcant pericardial eﬀusion, requiring either
percutaneous or surgical drainage, carrying a 4.8% procedu-
ral risk. Other adverse procedure related outcomes included
major bleeding requiring a transfusion of ≥2 units of
packed red cells or surgical intervention (3.5%), procedure-
related ischemic stroke (1.1%), device embolization (0.6%),
haemorrhagic stroke (0.2%), oesophageal tear (0.2%), and
procedure-related arrhythmia (0.2%). However, it should
be noted that over the study duration, the incidence of
major bleeding (3.5% versus 4.1%) and haemorrhagic stroke
(0.2% versus 2.5%) was less in the intervention group
compared to the control group. Further published data
by Reddy et al. [33] comparing data from the ﬁrst and
second half of the PROTECT-AF trial with the Continued
Access Protocol (CAP), suggests that device implantation is
associated with a learning phase for the device implanter
and that the incidence of adverse safety outcomes have
declined with increasing operator experience. The data
demonstrates adverse safety outcomes of 10.0%, 5.5%, and
3.7% in the ﬁrst and second halves of PROTECT AF and
CAP, respectively: highlighting a decline in adverse outcome
with increasing operator experience [33]. Furthermore, the
FDA have mandated a subsequent follow-on randomised
controlledtrial(PREVAIL),aimingtoenrolupto475patients
with nonvalvular AF with a CHADS2 score of at least 2
AND be eligible for warfarin. This is a higher risk group
than used in the PROTECT-AF trial. Patients will be ran-
domised in a 2:1 fashion to receive a WATCHMAN device
or warfarin only. The primary end-point is a composite
of ischaemic/haemorrhagic stroke, systemic embolism and
cardiovascular or unexplained death.
Early data from the ASA Plavix (ASAP) registry [34],
suggest that in patients with contraindications to warfarin
use, the Watchman closure device implantation is possible
with the use of 6 months of dual antiplatelet therapy (aspirin
and clopidogrel) followed by life-long aspirin thereafter.
The registry includes 82 patients at 4 European centers in
whom the device was successfully implanted with a median
followup is 6 months. In this cohort with limited followup,
2 patients suﬀered an ischemic stroke. In both cases, no
thrombus was demonstrable on the surface of the device
or in the left atrium on transesophageal echocardiography.
Device-related thrombus was found in 2 other patients
on routine follow-up transesophageal echocardiography.
Further data including longer-term followup is necessary in
order to ascertain the safety and feasibility of this approach
in patients with contraindications to warfarinisation.
3.4. AMPLATZER Cardiac Plug. The AMPLATZER cardiac
plug (St. Jude Medical, Plymouth, MN, USA) was developed
based on the AMPLATZER double-disk septal occluders (see
above) designed for closure of atrial septal defects and patent
foramen ovale. The AMPLATZER cardiac plug system like
the other left atrial appendage occluders is designed for im-
plantation through femoral venous access via the transseptal
route.
The device consists of a lobe, designed to sit within
the left atrial appendage, and an occlusive disc, which ﬁts
over the left atrial appendage oriﬁce. The lobe and disc are
connected by a central waist, with the lobe containing hooks
to ensure device position.
A retrospective review of the preregistry data demon-
strated good procedural success with successful device im-
plantation achieved in 132 of the 141 patients (94%) treated
[35]. Serious adverse outcomes occurred in 10 (7.0%)
patients, including 3 ischemic strokes, 2 device embolization
(both recaptured percutaneously), and 5 clinically signiﬁ-
cant pericardial eﬀusions. Minor complications included 4
clinically nonsigniﬁcant pericardial eﬀusions, 2 patients with
transient myocardial ischemia, and loss of the implant in the
venous system in one patient.
InterimdatafromtheAMPLATZERCardiacPlug’sEuro-
pean postmarket registry reveals similar procedural success
with no device embolizations during the implant procedure.
Procedure related adverse events were not signiﬁcantly
changed when compared to the previous data, occurring
in 8 out of the 145 registry patients (5.5%) within 7 days
after procedure. These consisted of 3 signiﬁcant pericardial
eﬀusions, 3 device embolizations, 1 cardiac perforation, and
1 arteriovenous ﬁstula. Three cases of thrombus on the
deviceandonecaseoflatedeviceembolizationweredetected
during the post 7-day followup (Figure 3).
The AMPLATZER cardiac plug has received European
regulatoryapprovalandisavailableforclinicaluseinEurope.
Additionally, the device is currently undergoing a phase
1 randomised controlled trial compared to conventionalCardiology Research and Practice 7
Figure 3: AMPLATZER cardiac plug. (AMPLATZER and St. Jude
Medical, Inc. Reprinted with permission of St. Jude Medical, ©
2011. All rights reserved).
warfarin therapy to obtain United States Food and Drug
Administration (FDA) approval.
3.5. Coherex Wave Crest. The Coherex Wave Crest left atrial
appendage occlusion system is a percutaneous transseptally
delivered left atrial appendage occluder, consisting of a
nitinol frame with retractable coils and anchors to enable
optimal device positioning. The device consists of a mul-
ticomposite membrane including a porous expanded poly-
tetraﬂuoroethylene on the left atrial side of the device,
nonporous expanded polytetraﬂuoroethylene barrier layer,
and a foam substrate on the left atrial appendage opposing
surface to minimise residual leaks.
Initial pilot phase results in 9 patients demonstrated 2
embolic events, prompting device modiﬁcations prior to
further trials. These modiﬁcations included provision of a
bidirectionalanchor,reﬁnedshape,increasedradialstrength,
and improved occluder geometry.
The Coherex Wave Crest has thus far been implanted
in 52 patients. Limited outcome data is currently available
with data in a subset of 10 patients treated at a single
institution revealing one embolic event with no cases of
pericardial eﬀusion or thrombosis [36]. Further clinical trial
data regarding device safety and eﬃcacy is currently pending
(Figure 4).
3.6. LARIAT. The LARIAT procedure (SentreHEART Inc.,
Palo Alto, CA, USA) for percutaneous left atrial appendage
closure requires both endocardial and epicardial access.
A preoperative CT is required to exclude large bilobar
appendages and other anatomic variants. A magnet-tipped
guide wire system is placed at the endocardial surface of the
left atrial appendage apex, via femoral venous access and a
transseptal puncture. A second magnet-tipped guide wire
system is percutaneously introduced into the pericardium
overlying the left atrial appendage apex. This requires an
anterior approach to percutaneous pericardial access using
a 17G Tuohy needle. The magnet-tipped wires, which
Figure 4: Coherex Wave Crest. (Image courtesy of Coherex Medi-
cal).
establish contact easily, align the endocardial and epicardial
aspect of the left atrial appendage under ﬂuoroscopy. The
LARIAT Suture Delivery Device is guided over the left atrial
appendage in an over-the-wire approach to slip a pretied
suture loop over the appendage under transesophageal ech-
ocardiographic guidance to achieve appendage closure. The
LARIAT delivery system can be opened and closed to allow
optimal device positioning prior to device deployment [37,
38].
Duetotheneedforpericardialaccess,thosepatientswith
possible pericardial adhesions are unsuitable for the LARIAT
procedure. This includes those with a prior history of cardiac
surgery, pericarditis, or chest radiotherapy.
Early human experience demonstrated successful left
atrial appendage ligation in 78 of 82 patients undergoing
this procedure [39]. The remaining 4 patients suﬀered
from access-related complications including 2 patients with
hemopericardium, 1 patient with pericardial adhesions, and
1 patient in whom it was not possible to perform transseptal
catheterization. A further 13 were excluded from undergoing
this procedure, due to anatomical unsuitability and left atrial
appendage thrombus on the preprocedure transesophageal
echocardiogram. Of the 70 patients undergoing successful
left atrial appendage ligation who had 1 month trans-
esophageal echocardiographic followup, 96% had complete
acute closure of the left atrial appendage with the remaining
4% patients having a less than 2mm jet identiﬁed by colour
ﬂow Doppler. There were no device-related complications
(Figure 5).
No published postprocedural follow-up data is currently
available, and further results are currently awaited.
4. Conclusions
Surgical methods of LAA closure have been used for more
than 20 years, with varying degrees of success. Historically
LAA excision has been more successful than exclusion;
however, newer surgical techniques are continuously being
studied. A number of percutaneous left atrial appendage
closure devices are currently undergoing clinical trial. Only
three of these device systems are currently available for
commercial use. The LARIAT suture delivery system is
the only device system with both FDA and European CE
mark approval for its use. The remaining two devices8 Cardiology Research and Practice
Figure 5: LARIAT (Image courtesy of SentreHEART).
(WATCHMAN and AMPLATZER cardiac plug) carry Euro-
pean regulatory approval for this indication. Percutaneous
left atrial appendage closure devices are usually associated
with high procedural success rates. However, they are also
associated with a signiﬁcant incidence of peri-procedural
adverse events; including signiﬁcant pericardial eﬀusions,
major bleeding, procedure-related ischemic stroke, device
embolization, and death. Cardiac imaging plays a vital role
in assessing anatomical suitability and guiding placement of
these devices.
The European Society of Cardiology Guidelines for the
management of Atrial Fibrillation suggests that patients with
contraindications to chronic oral anticoagulation might be
considered as candidates for left atrial appendage occlusion
[40]. The 2011 ACCF/AHA/HRS Focused Update on the
Management of Patients with Atrial Fibrillation carries no
recommendationsregardingpercutaneousleftatrialappend-
age closure, with the WATCHMAN device noted as currently
pending FDA approval [41]. With regards to surgery, the
ACC/AHA 2006 Guidelines for the Management of Patients
with Valvular Heart Disease recommend patients, undergo
amputation of the LAA to when a patient undergoes mitral
valvesurgerytoreducetheincidenceofpostoperativethrom-
boembolic events [42].
There is a subset of patients who are at a high risk of
both cardioembolic stroke and bleeding. It is likely that these
patients would be ideal candidates for LAA closure; however,
its role still needs to be properly deﬁned.
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